Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 772

1.

Is there a place for postmenopausal hormone therapy use in women with lupus?

Gompel A, Piette JC.

Panminerva Med. 2008 Sep;50(3):247-54. Review.

PMID:
18927529
2.
3.

Transdermal hormone therapy and the risk of stroke and venous thrombosis.

Speroff L.

Climacteric. 2010 Oct;13(5):429-32. doi: 10.3109/13697137.2010.507111.

PMID:
20670199
4.

Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.

Harman SM, Naftolin F, Brinton EA, Judelson DR.

Ann N Y Acad Sci. 2005 Jun;1052:43-56.

PMID:
16024750
5.

Menopause and stroke and the effects of hormonal therapy.

Lobo RA.

Climacteric. 2007 Oct;10 Suppl 2:27-31. Review.

PMID:
17882669
6.

Postmenopausal hormone therapy: cardiovascular risks.

[No authors listed]

Prescrire Int. 2003 Apr;12(64):65-9.

PMID:
12674130
7.

Systemic lupus erythematosus and hormone replacement therapy.

Gompel A, Piette JC.

Menopause Int. 2007 Jun;13(2):65-70. Review.

PMID:
17540136
8.

Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.

[No authors listed]

Prescrire Int. 2004 Jun;13(71):106-9.

PMID:
15233153
9.

Estrogen therapy in systemic lupus erythematosus.

Askanase AD.

Treat Endocrinol. 2004;3(1):19-26. Review.

PMID:
15743110
10.

Is the WHI relevant to HRT started in the perimenopause?

Harman SM, Brinton EA, Clarkson T, Heward CB, Hecht HS, Karas RH, Judelson DR, Naftolin F.

Endocrine. 2004 Aug;24(3):195-202.

PMID:
15542885
11.

Recent epidemiological evidence relevant to the clinical management of the menopause.

Shapiro S.

Climacteric. 2007 Oct;10 Suppl 2:2-15. Review.

PMID:
17882666
12.

New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT.

Maturitas. 2005 Sep 16;52(1):1-10. Review.

PMID:
15963666
13.

A comparative review of the risks and benefits of hormone replacement therapy regimens.

Warren MP.

Am J Obstet Gynecol. 2004 Apr;190(4):1141-67. Review.

PMID:
15118656
14.

Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review.

Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P.

Fertil Steril. 2008 Sep;90(3):642-72. Epub 2007 Oct 17. Review.

PMID:
17923128
15.

Indications for hormone therapy: the post-Women's Health Initiative era.

Reed SD, Newton KM, Lacroix AZ.

Endocrinol Metab Clin North Am. 2004 Dec;33(4):691-715. Review.

PMID:
15501641
16.

Postmenopausal hormone therapy: new questions and the case for new clinical trials.

Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, Miller VM, Naftolin F, Santoro N.

Menopause. 2006 Jan-Feb;13(1):139-47.

PMID:
16607110
17.

Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.

Banks E, Canfell K.

Am J Epidemiol. 2009 Jul 1;170(1):24-8. doi: 10.1093/aje/kwp113. Epub 2009 May 25.

18.

Postmenopausal hormone therapy: from monkey glands to transdermal patches.

Davis SR, Dinatale I, Rivera-Woll L, Davison S.

J Endocrinol. 2005 May;185(2):207-22. Review.

19.

Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.

Rosano GM, Maffei S, Andreassi MG, Vitale C, Vassalle C, Gambacciani M, Stramba-Badiale M, Mercuro G.

J Cardiovasc Med (Hagerstown). 2009 Jan;10(1):85-92. doi: 10.2459/JCM.0b013e328313e979.

PMID:
19145119
20.

WHI risks: any relevance to menopause management?

Burger HG.

Maturitas. 2007 May 20;57(1):6-10. Epub 2007 Mar 21.

PMID:
17368974
Items per page

Supplemental Content

Write to the Help Desk